Last updated on January 2019

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Brief description of study

This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies

Clinical Study Identifier: NCT03453619

Find a site near you

Start Over

Apellis Investigational Site

Shreveport, LA United States
  Connect »